Unknown

Dataset Information

0

Suppression of Th17-polarized airway inflammation by rapamycin.


ABSTRACT: Because Th17-polarized airway inflammation correlates with poor control in bronchial asthma and is a feature of numerous other difficult-to-treat inflammatory lung diseases, new therapeutic approaches for this type of airway inflammation are necessary. We assessed different licensed anti-inflammatory agents with known or expected efficacy against Th17-polarization in mouse models of Th17-dependent airway inflammation. Upon intravenous transfer of in vitro derived Th17 cells and intranasal challenge with the corresponding antigen, we established acute and chronic murine models of Th17-polarised airway inflammation. Consecutively, we assessed the efficacy of methylprednisolone, roflumilast, azithromycin, AM80 and rapamycin against acute or chronic Th17-dependent airway inflammation. Quantifiers for Th17-associated inflammation comprised: bronchoalveolar lavage (BAL) differential cell counts, allergen-specific cytokine and immunoglobulin secretion, as well as flow cytometric phenotyping of pulmonary inflammatory cells. Only rapamycin proved effective against acute Th17-dependent airway inflammation, accompanied by increased plasmacytoid dendritic cells (pDCs) and reduced neutrophils as well as reduced CXCL-1 levels in BAL. Chronic Th17-dependent airway inflammation was unaltered by rapamycin treatment. None of the other agents showed efficacy in our models. Our results demonstrate that Th17-dependent airway inflammation is difficult to treat with known agents. However, we identify rapamycin as an agent with inhibitory potential against acute Th17-polarized airway inflammation.

SUBMITTER: Joean O 

PROVIDER: S-EPMC5681547 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Suppression of Th17-polarized airway inflammation by rapamycin.

Joean Oana O   Hueber Anja A   Feller Felix F   Jirmo Adan Chari AC   Lochner Matthias M   Dittrich Anna-Maria AM   Albrecht Melanie M  

Scientific reports 20171110 1


Because Th17-polarized airway inflammation correlates with poor control in bronchial asthma and is a feature of numerous other difficult-to-treat inflammatory lung diseases, new therapeutic approaches for this type of airway inflammation are necessary. We assessed different licensed anti-inflammatory agents with known or expected efficacy against Th17-polarization in mouse models of Th17-dependent airway inflammation. Upon intravenous transfer of in vitro derived Th17 cells and intranasal challe  ...[more]

Similar Datasets

| S-EPMC4209254 | biostudies-literature
| S-EPMC5968555 | biostudies-literature
| S-EPMC7946768 | biostudies-literature
| S-EPMC4233308 | biostudies-literature
| S-EPMC11348649 | biostudies-literature
| S-EPMC2000444 | biostudies-literature
| S-EPMC7747217 | biostudies-literature
| S-EPMC2442746 | biostudies-literature
| S-EPMC395932 | biostudies-other
| S-EPMC3088485 | biostudies-literature